MTOR and metabolic dysfunction-associated steatohepatitis: Given the considerably inconsistent findings regarding histopathological outcomes, gene mRNA (namely, Mtor and Galr2), and oxidative stress across the experimental sets, both our research team and other scientists posit that MASLD, the transition from MASLD to MASH (i.e., early-stage MASH), and advanced MASH (i.e., later-stage MASH) represent distinct and complex phenotypes (Martin et al., 2021; Arora et al., 2023).